The FDA approved daraxonrasib for defined groups of adults with metastatic pancreatic adenocarcinoma after a 500-person trial doubled median survival versus chemotherapy. The once-daily RAS inhibitor is not a cure, carries serious risks and has a list price near $39,800 per month.
The FDA approved daraxonrasib for defined groups of adults with metastatic pancreatic adenocarcinoma after a 500-person trial doubled median survival versus chemotherapy. The once-daily RAS inhibitor is not a cure, carries serious risks and has a list price near $39,800 per month.
A Pancreatic Cancer Drug That Doubled Median Survival Is Now Approved
Chemists have developed a one-step reaction that replaces boron with carbon inside a molecular ring while preserving the group attached to it. The method could make drug-candidate comparisons faster and cleaner, but it has so far been demonstrated only in laboratory chemistry, not in medicines or patients.
Chemists have developed a one-step reaction that replaces boron with carbon inside a molecular ring while preserving the group attached to it. The method could make drug-candidate comparisons faster and cleaner, but it has so far been demonstrated only in laboratory chemistry, not in medicines or patients.
Scientists Replaced One Atom Without Rebuilding the Molecule. Drug Hunters Could Gain a Faster Shortcut
An international study of more than 600 childhood tumours identified mutation patterns linked to specific cancer treatments, sometimes within 91 days. The findings may support earlier monitoring of resistant disease, but they do not show that chemotherapy causes every relapse or provide a clinical test yet.
An international study of more than 600 childhood tumours identified mutation patterns linked to specific cancer treatments, sometimes within 91 days. The findings may support earlier monitoring of resistant disease, but they do not show that chemotherapy causes every relapse or provide a clinical test yet.
Chemotherapy Can Leave a DNA Fingerprint in Childhood Tumours Within Months
